Gilead Sciences (NASDAQ:GILD) Given New $75.00 Price Target at UBS Group

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target decreased by UBS Group from $81.00 to $75.00 in a report issued on Wednesday, Benzinga reports. UBS Group currently has a neutral rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. Oppenheimer lowered their price objective on Gilead […]

Related Keywords

United States ,Merdad Parsey ,Complera Eviplera ,Etesian Wealth Advisors Inc ,Gilead Sciences Trading Down ,Wealth Partners ,Altshuler Shaham Ltd ,Gilead Sciences Increases Dividend ,Gilead Sciences ,Wells Fargo Company ,Insider Transactions At Gilead Sciences ,Nilsine Partners ,Financial Counselors Inc ,News Ratings For Gilead Sciences Daily ,Analyst Recommendations For Gilead Sciences ,Gilead Sciences Inc ,Free Report ,Sciences Trading Down ,Get Free Report ,Shaham Ltd ,Wealth Advisors ,Revolve Wealth Partners ,Gilead Sciences Daily ,